Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
MDxHealth (MDXH)
NASDAQ:MDXH
Holding MDXH?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.19Last Year’s EPS
-$0.39Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: 8.65%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, increased test volumes, and a successful capital raise, which led to an increase in revenue guidance. However, there was a noted decline in gross margins and an increase in operating loss. Overall, the positive aspects, particularly the substantial revenue growth and raised guidance, outweighed the lowlights.Company Guidance
During the MDxHealth third-quarter 2024 earnings call, CEO Michael McGarrity provided guidance indicating robust and sustainable revenue growth driven by strong performance across their diagnostic test portfolio. The company reported a year-over-year revenue increase of 21%, with third-quarter revenues amounting to $23.3 million. Notably, the total billable volume for the quarter was 22,795 tests, marking a 30% unit growth, split between tissue-based tests like Confirm mdx and GPS, which grew by 36%, and liquid-based tests such as Select mdx, Resolve mdx, and Germline, which grew by 24%. The company raised its 2024 revenue guidance from $87 million to $89 million, reflecting expected year-over-year top-line growth exceeding 25%. McGarrity emphasized their strategic focus on execution and growth, supported by a strong cash position of $53.5 million, which includes $40 million raised in gross proceeds during the quarter. The company aims to achieve adjusted EBITDA positivity in the first half of 2025.Strong Year-over-Year Revenue Growth
MDxHealth reported a year-over-year revenue growth of 21%, or 27% when adjusted for Select revenue backlog, indicating strong commercial execution and market positioning.
Increased Test Volumes
Total billable volume for the quarter was 22,795 tests, with tissue-based tests increasing by 36% and liquid-based tests by 24% over the prior year period.
Successful Capital Raise
MDxHealth raised $40 million in gross proceeds during the quarter, increasing the cash position to $53.5 million, providing a runway to meet future obligations and reach EBITDA positivity.
Raised Revenue Guidance
The company raised its 2024 revenue guidance from $85-87 million to $87-89 million, reflecting confidence in achieving greater than 25% year-over-year top-line growth.
---
MDXH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MDXH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $2.08 | $2.09 | +0.48% |
| Aug 21, 2024 | $3.27 | $2.87 | -12.23% |
| May 01, 2024 | $2.50 | $2.67 | +6.80% |
| Mar 06, 2024 | $3.73 | $3.08 | -17.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does MDxHealth (MDXH) report earnings?
MDxHealth (MDXH) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is MDxHealth (MDXH) earnings time?
MDxHealth (MDXH) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDXH EPS forecast?
MDXH EPS forecast for the fiscal quarter 2024 (Q4) is -$0.19.
---